The evidence leans constructive7 supporting, 1 against, 0 worth knowing
Supporting
trading 59% above its 200-day average
sitting at 96% of its 52-week range, with little overhead supply from trapped buyers
up 98% over twelve months
matches growing fast and near a high, which has beaten the market by +0.97 points over 20 sessions across 15,457 past signals
7 of the scans it matches have a positive measured record
5 independent kinds of evidence agree today, which is uncommon
revenue grew 42% year on year in the quarter ending 31 December 2024
Against
net margin has narrowed from 8.3% to 7.1% across four quarters
Worth knowing
nothing the data supports either way
The most recent financials the exchange publishes for IRISDOREME are 20 months old, so everything above about the business is history rather than a current read.
What would change this read: a close below 39, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working6
Revenue rose 42.1% year on year, from Rs 23 cr to Rs 33 cr.
+42.1%Rs 23 crRs 33 cr
Net profit rose 19.6% year on year, from Rs 2 cr to Rs 2 cr.
+19.6%Rs 2 crRs 2 cr
Trading 58.9% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+58.9%
Within 2.0% of its 52-week high.
-2.0%
Up 97.6% over the past year.
+97.6%
3 different kinds of evidence point at it tonight, not 3 versions of the same one.
3 families
Needs watching3
Profit grew slower than revenue, +19.6% against +42.1%.
+19.6%+42.1%
Net margin moved from 8.5% to 7.1%.
8.5%7.1%
A warning rule fires on it tonight: stretched far above trend.
Stretched far above trend
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 4 of these 4 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
9 of 47 matched on 10 Sep
IRISDOREME matches 9 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
IRISDOREME trades at 42× trailing earnings, above its median of 22× over this window — 87% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
The business
from the company’s filed results
These figures are 20 months old. The most recent quarter the exchange feed publishes for this company ended 2024-12-31. Treat the growth rates below as history, not as a current read — the business may look quite different now.
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 42% against the same quarter a year earlier
profit rose 20% year on year
Going against it
net margin narrowed from 9.3% to 7.1%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q3 FY25
31 Dec · standalone
33
3
2
0.29
7.1%
Q2 FY25
30 Sep · standalone
41
5
4
0.47
9.3%
Q1 FY25
30 Jun · standalone
31
3
2
0.30
7.7%
Q4 FY24
31 Mar · standalone
42
5
3
0.43
8.3%
Q3 FY24
31 Dec · standalone
23
3
2
0.24
8.5%
Q2 FY24
30 Sep · standalone
32
5
4
0.45
11.4%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+17.4%
Versus 200-day average+58.9%
Below 52-week high-2.0%
Above 52-week low+123.8%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)70.4
Higher closes in last 52 of 5
Six-month return+104.77%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.79%
Volume versus 20-day1.2x
Median daily turnoverRs 6.5 cr
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
4 Sep
3
Closing in on a 52-week high, Made a new 52-week high today, Growing fast and near a high
3 Sep
2
Closing in on a 52-week high, Growing fast and near a high